Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-743-6 | CAS number: 149-57-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP compliant, near guideline study, with minor restrictions in design and/or reporting but otherwise adequate for assessment.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 988
- Report date:
- 1988
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EPA OTS 795.2600 (Subchronic Oral Toxicity Test)
- GLP compliance:
- yes
- Remarks:
- Health and Environmental Laboratories, Eastman Kodak Company
- Limit test:
- no
Test material
- Reference substance name:
- 2-ethylhexanoic acid
- EC Number:
- 205-743-6
- EC Name:
- 2-ethylhexanoic acid
- Cas Number:
- 149-57-5
- Molecular formula:
- C8H16O2
- IUPAC Name:
- 2-ethylhexanoic acid
- Details on test material:
- - Purity: 99.9% (±0.05%; GC)
- The test material is stable in open feeders for at least 7 days (GC)
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- B6C3F1
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Wilmington, MA
- Age at study initiation: 6 weeks
- Weight at study initiation: males: 23 (± 0.8) g; females: 19 (± 0.8) g
- Housing: individually
- Diet (e.g. ad libitum): Agway Prolab Animal Diet (RMH 3200), certified ground chow; ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°F): 68-72
- Humidity (%): 46-67
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
Diets were prepared containing 0.0, 0.1, 0.5 or 1.5% of the test material. The diets were frozen in closed amber glass bottles until used. The test material was stable for at least 35 days in the diets when refrigerated. Stability, homogeneity and concentration analyses were conducted using GC.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analyzed concentrations (mean ± SD; GC): 0.091 (± 0.004), 0.45 (± 0.02) and 1.45 (± 0.05)%
- Duration of treatment / exposure:
- 91-93 days
- Frequency of treatment:
- 7 days/week
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
0, 0.1, 0.5 and 1.5%. 28-day recovery groups: 0 and 1,5%
Basis:
nominal in diet
- Remarks:
- Doses / Concentrations:
0, 0.091, 0.45 and 1.45% (recovery groups: 0 and 1.45%)
Basis:
other: analyzed in diet
- Remarks:
- Doses / Concentrations:
0, 180, 885 and 2728 mg/kg/day for males (recovery: 0 and 2895 mg/kg/day); 0, 205, 1038 and 3139 mg/kg/day for females (recovery: 0 and 3101 mg/kg/day)
Basis:
other: actual dose
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, plain diet
- Details on study design:
- - Dose selection rationale: based on a 14-day feeding study in mice
- Post-exposure recovery period in satellite groups: 28-29 days - Positive control:
- Not included
Examinations
- Observations and examinations performed and frequency:
- CLINICAL OBSERVATIONS: Yes
- Detailed observations: on the mornings of body weight measurement.
- Cage side observations: every workday afternoon and on mornings on which body weights were not collected. Animals were checked for mortality on weekends.
BODY WEIGHT: Yes
- Time schedule for examinations: days 0, 3, 7, and at least once weekly thereafter.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Feed weights (g) were collected on days 3, 7, and at least once weekly thereafter.
OPHTHALMOSCOPIC EXAMINATION: Yes, using an indirect ophthalmoscope after dilation of the pupils with 1% Mydriacyl.
All mice were examinde prior to the start of the study. During the last week of exposure, five male and five female non-recovery animals from each dose level were examined.
HAEMATOLOGY: Yes
- Time schedule for collection of blood: at necropsy
- Anaesthetic used for blood collection: Yes (CO2 anaesthesia)
- Animals fasted: overnight
- How many animals: five animals per sex, per dose.
- Parameters: hemoglobin concentration, hematocrit, red blood cell count, white blood cell count, differential white blood cell count, platelet count, red blood cell indices, and examination of the blood smears for cellular morphology.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: at necropsy
- Animals fasted: overnight
- How many animals: five animals per sex per dose
- Parameters: Non-recovery groups: aspartate aminotransferase, alanine aminotransferase, total bilirubin, total protein, albumin, creatinine, urea nitrogen, glucose, gamma glutamyl transpeptidase, triglycerides, cholesterol, sodium, potassium, chloride, calcium and phosphorus. Recovery groups: alanine aminotransferase, total bilirubin, urea nitrogen, triglycerides, cholesterol.
URINALYSIS: Yes
In the week prior to termination of exposure, five males and five females from each dose group were place in metabolism cages for 24-hour urine collections. Parameters: specific gravity, osmolality, volume, glucose, bilirubin, ketones, blood, protein, urobilinogen, nitrite, leukocytes and pH. - Sacrifice and pathology:
- Organ weights: liver, kidneys, adrenal glands, testes, ovaries, brain.
Histopathology: all non-recovery high-dose and control animals: trachea, lungs, heart, aorta, esophagus, stomach, duodenum, jejunum, ileum, cecum, colon, rectum, pancreas, liver, salivary glands, kidneys, urinary bladder, pituitary gland, adrenal glands, thyroid glands, parathyroid glands, thymus, spleen, mesenteric lymph nodes, bone marrow (femoral), brain (including sections of medulla/pons, cerebellar cortex, and cerebral cortex), sciatic nerve, quadriceps femoris, testes, ovaries, vagina, uterus, fallopian tubes, sternum with bone marrow, and gross lesions.
The liver, kidneys, lungs, target organs, and gross lesions for animals from all dose levels were examined.
Because no signs of toxicity or target organ involvement was observed, no histopathology was performed on cervical/mid-thoracic/lumbar spinal cord, epididymides, male accessory sex glands, male mammary gland, female mammary gland, femur (including articular surface), skin, and exorbital lachrymal glands.
For recovery animals, histopathology was performed on the liver, kidneys, lungs, and gross lesions. - Statistics:
- Means were calculated for body weight, feed consumption, and organ weights. Numerical data were evaluated using Bartlett's test, one-way ANOVA, and Duncan's multiple range test.
Results and discussion
Results of examinations
- Details on results:
- CLINICAL SIGNS AND MORTALITY
No mortality occured during the study.
BODY WEIGHT AND WEIGHT GAIN
A reduced mean body weight was observed in males and females of the high-dose group (5.2% and 13.8% below control weights on day 91, respectively) and in females of the mid-dose group (5.6% below control weights on day 91). At the end of the recovery period, body weight was still 4.7% and 10.1% below control weights in males and females of the high-dose group, respectively.
FOOD CONSUMPTION
In males of the high-dose group, feed consumption was below control levels at several time points. In females of the high-dose group, this occured once in the main study group, but consumption was almost continuously below control level in the recovery group. At the end of the recovery period, high-dose males consumed slightly more than the control and high-dose females consumed slightly less the the control group, but neither difference was statistically significant.
CLINICAL CHEMISTRY
In high-dose males, bilirubin and triglyceride levels were reduced. Cholesterol was elevated in the mid- and high-dose males and alanine aminotransferase (ALT) only in the high-dose group.
Females of the high-dose group exhibited increased levels of urea nitrogen. Bilirubin and triglyceride levels were below control levels in the mid- and high-dose groups, and cholesterol levels were higher relative to controls.
In the recovery males, ALT, bilirubin and triglycerides were lower than controls for the high-dose group, and cholesterol levels were increased, though not statistically significant. In the recovery females, no effects were observed.
URINALYSIS
Dose-dependent elevations in ketone levels were noted in females, which returned to control levels by the end of the recovery period.
ORGAN WEIGHTS
- Liver weights were increased in high-dose animals. At the mid-dose level, relative liver (to body) weight was increased in males and females and absolute and relative (to brain) liver weights were increased in mid-dose males only. At the end of the recovery period, liver weight differences had largely disappeared.
- Differences in kidney weight (viz. increased relative kidney/body weight in mid- and high-dose females, increased in relative kidney/brain weight in high-dose females, decreased relative kidney/brain weight in high-dose males at the end of the recovery period) reflect differential growth in body and brain weights rather than any significant differrences in kidney weight. This also applies to the observed decrease in adrenal gland weight in mid- and high-dose females, and to the increase in relative testes weight in the high-dose males after the exposure period.
- Absolute brain weight for the high-dose females was decreased at the end of exposure, but not after the recovery period. In the high-dose males, an increased relative brain/body weight was observed at the end of exposure and after the recovery phase. These differences reflect growth retardation early in the animals' lives.
HISTOPATHOLOGY: NON-NEOPLASTIC
Hepatocyte hypertrophy with dose-dependent severitywas observed in all animals of the high-dose group and in males of the mid-dose group. The hypertrophy was characterized by an increase in the cell size with compression of the adjoining sinusoids. Affected hepatocytes were primarily located in the portal area, but in the high-dose group the lesions were diffuse and more eosinophilic. Furthermore, a decreased incidence of small cytoplasmic vacuoles was observed in a dose-dependent manner.
Slight increases in cytoplasmic basophilia of the proximal convoluted tubules were observed in the kidneys of the high-dose group. The same cells contained small numbers of cytoplasmic vacuoles, brush borders were absent and nuclei were slightly enlarged and vesicular with marginated chromatin (4/10 males and females were affected).
Stomach lesions in high-dose males consisted of minimal acanthosis and hyperkeratosis of the non-glandular forestomach (6/10 animals were affected).
At the end of the recovery period, the observed changes were largely reversed. Single animals still showed hepatocyte hypertrophy and decreased severity and amount of vacuolization.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 200 mg/kg bw/day (actual dose received)
- Sex:
- male/female
- Basis for effect level:
- other: Reduced feed consumption and decreased rate of body weight gain
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
The liver enlargement was considered to be primarily an adaptive change rather than a toxic effect.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.